Juniper
Inno Therapeutics, an emerging leader in drug, vaccine, and cellular therapeutic research and development, marked a major milestone today with the successful signing and exchange ceremony of multiple strategic collaborations with esteemed local and international partners.
Held at M World Hotel, the ceremony signifies Inno Therapeutics’ steadfast commitment to accelerating scientific innovation, advancing translational research, and strengthening Malaysia’s position as a hub for cutting-edge biopharmaceutical development.
The event witnessed the signing of collaboration agreements between Inno Therapeutics and several prestigious partners, including:
- University of Malaya (UM)
- Universiti Malaysia Sabah (UMS)
- Universiti Tunku Abdul Rahman (UTAR)
- Taiwan Bio Therapeutics
- BioMab Inc.
- Reyoung Bio Sdn Bhd
Through these partnerships, Inno Therapeutics aims to drive breakthroughs in areas such as:
- Stem cell and exosome-based therapies • Vaccine development and clinical translation
- Advanced cell culture systems and biomedical innovations
- Translational research for regenerative medicine and oncology
Highlighting the ceremony, Inno Therapeutics and Reyoung Bio Sdn Bhd announced a joint commitment to invest up to RM10 million over the next five years for a collaborative research and development project focused on advanced cosmetic and aesthetic product innovations.
This landmark initiative will leverage cutting-edge biotechnology and clinical expertise to deliver next-generation aesthetic solutions with global market potential. “Today’s ceremony is not just about agreements—it’s about shared visions, combined strengths, and the collective pursuit of transformative healthcare solutions,” said Dr. Evan Cheah, CEO and Founder of Inno Therapeutics.
“Together with our partners, we are building a future where scientific excellence knows no boundaries.” Inno Therapeutics is a Bio-based Accelerator (BBA) company — part of a dedicated programme by the Malaysian Bioeconomy Development Corporation (Bioeconomy Corporation) that supports high-potential bio-based companies through mentorship, facilitation, and market access. Bioeconomy Corporation is the lead agency driving bio-based and biotechnology industry growth under the purview of the Ministry of
Science, Technology and Innovation (MOSTI).
“Each partner institution and organization here today bring a unique strength.:
University Malaya, with its national reputation of being the best university in Malaysia and with a distinguished research history, from Phytolab (IFMNATPROLAB),. We will contribute a crucial academic depth and analytical rigor to our collective scientific pursuit and research standard.
UMS regional expertise, particularly in biotechnological research and years of precious experience bring a dimension of expertise to our research project. Taiwan Bio Therapeutics bring world-class capabilities in regenerative medicine and immunotherapy – technologies that we are eager to co-develop and localize for a broader impact.
BioMab’s platforms will be a cornerstone, our development and testing of new biologics.
Reyoung Bio with strong commitments into R&D reinvestment, ensures our discoveries are not just conceptual – but manufacturable, scalable, and accessible”, Dr. Evan Cheah added.
Bioeconomy Corporation’s Chief Executive Officer, En. Mohd Khairul Fidzal Abdul Razak said that the success of Inno Therapeutics is a reflection of the organisation’s commitment to building a stronger, innovation-driven healthcare ecosystem in biotechnology.
“Inno Therapeutics is a shining example of the kind of impact we aim to drive through the BBA programme — bridging academia and industry, connecting local and global players, and delivering real health solutions for Malaysians. These collaborations can accelerate breakthroughs in local healthcare advancements, and we at Bioeconomy Corporation will continue supporting Inno Therapeutics through ongoing facilitation and by connecting them to key opportunities within the bioeconomy,” he added. “We are excited to embark on this strategic collaboration with Inno Therapeutics, which reflects our shared commitment to innovation and excellence in the cosmetic and aesthetics sector. Through this joint investment, we aim to pioneer advanced, science-driven products that meet the evolving needs of consumers both locally and internationally. We believe that by combining Reyoung Bio’s expertise with Inno Therapeutics’ cutting-edge research capabilities, we can accelerate the development of next-generation solutions that redefine the standards of beauty and wellness,” said Belle Lim, Director of Reyoung Bio Sdn. Bhd.
The strategic collaborations encompass joint research initiatives, technology transfers, clinical trial collaborations, and talent development programs, designed to fuel local innovation while contributing to global health advancements.
This momentous occasion reflects Inno Therapeutics’ continuous mission to bridge academic research with industry needs, fostering an ecosystem where discoveries can be translated into impactful therapies for patients worldwide.
